{
    "title": "Better Pharmaceuticals for Children Act",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Better Pharmaceuticals for Children \nAct''.\n\nSEC. 2. PEDIATRIC STUDIES MARKETING EXCLUSIVITY.\n\n    Chapter V of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n351 et seq.) is amended by inserting after section 505 the following \nnew section:\n\n``SEC. 505A. PEDIATRIC STUDIES OF DRUGS.\n\n    ``(a) Market Exclusivity for New Drugs.--If, prior to approval of \nan application that is submitted under section 505(b)(1) the Secretary \ndetermines that information relating to the use of a drug in the \npediatric population may produce health benefits in that population, \nthe Secretary makes a written request for pediatric studies (which may \ninclude a time frame for completing such studies), and such studies are \ncompleted within any such time frame and the reports thereof submitted \nin accordance with subsection (d)(2) or completed within any such time \nframe and the reports thereof are accepted in accordance with \nsubsection (d)(3)--\n            ``(1)(A) the period during which an application may not be \n        submitted under subsections (c)(3)(D)(ii) and (j)(4)(D)(ii) of \n        section 505 shall be five years and six months rather than five \n        years, and the references in subsections (c)(3)(D)(ii) and \n        (j)(4)(D)(ii) of section 505 to four years, to forty-eight \n        months, and to seven and one-half years shall be deemed to be \n        four and one-half years, fifty-four months, and eight years, \n        respectively; or\n            ``(B) the period of market exclusivity under subsections \n        (c)(3)(D) (iii) and (iv) and (j)(4)(D) (iii) and (iv) of \n        section 505 shall be three years and six months rather than \n        three years; and\n            ``(2)(A) if the drug is the subject of--\n                    ``(i) a listed patent for which a certification has \n                been submitted under section 505(b)(2)(A)(ii) or \n                (j)(2)(A)(vii)(II) and for which pediatric studies were \n                submitted prior to the expiration of the patent \n                (including any patent extensions), or\n                    ``(ii) a listed patent for which a certification \n                has been submitted under section 505(b)(2)(A)(iii) or \n                section 505(j)(2)(A)(vii)(III),\n        the period during which an application may not be approved \n        under section 505(c)(3) or section 505(j)(4)(B) shall be \n        extended by a period of six months after the date the patent \n        expires (including any patent extensions); or\n            ``(B) if the drug is the subject of a listed patent for \n        which a certification has been submitted under section \n        505(b)(2)(A)(iv) or section 505(j)(2)(A)(vii)(IV), and in the \n        patent infringement litigation resulting from the certification \n        the court determines that the patent is valid and would be \n        infringed, the period during which an application may not be \n        approved under section 505(c)(3) or section 505(j)(4)(B) shall \n        be extended by a period of six months after the date the patent \n        expires (including any patent extensions).\n    ``(b) Secretary To Develop List of Drugs for Which Additional \nPediatric Information May Be Beneficial.--Not later than 180 days after \nthe date of enactment of this section, the Secretary, after \nconsultation with experts in pediatric research (such as the American \nAcademy of Pediatrics, the Pediatric Pharmacology Research Unit \nNetwork, and the United States Pharmacopoeia) shall develop and publish \nan initial list of approved drugs for which additional pediatric \ninformation may produce health benefits in the pediatric population. \nThe Secretary shall annually update the list.\n    ``(c) Market Exclusivity for Already-Marketed Drugs.--If the \nSecretary makes a written request for pediatric studies (which may \ninclude a time frame for completing such studies) concerning a drug \nidentified in the list described in subsection (b) to the holder of an \napproved application under section 505(b)(1) for the drug, the holder \nagrees to the request, and the studies are completed within any such \ntime frame and the reports thereof submitted in accordance with \nsubsection (d)(2) or completed within any such time frame and the \nreports thereof accepted in accordance with subsection (d)(3)--\n            ``(1)(A) the period during which an application may not be \n        submitted under subsections (c)(3)(D)(ii) and (j)(4)(D)(ii) of \n        section 505 shall be five years and six months rather than five \n        years, and the references in subsections (c)(3)(D)(ii) and \n        (j)(4)(D)(ii) of section 505 to four years, to forty-eight \n        months, and to seven and one-half years shall be deemed to be \n        four and one-half years, fifty-four months, and eight years, \n        respectively; or\n            ``(B) the period of market exclusivity under subsections \n        (c)(3)(D) (iii) and (iv) and (j)(4)(D) (iii) and (iv) of \n        section 505 shall be three years and six months rather than \n        three years; and\n            ``(2)(A) if the drug is the subject of (i) a listed patent \n        for which a certification has been submitted under section \n        505(b)(2)(A)(ii) or (j)(2)(A)(vii)(II) and for which pediatric \n        studies were submitted prior to the expiration of the patent \n        (including any patent extensions), or (ii) a listed patent for \n        which a certification has been submitted under section \n        505(b)(2)(A)(iii) or section 505(j)(2)(A)(vii)(III), the period \n        during which an application may not be approved under section \n        505(c)(3) or section 505(j)(4)(B) shall be extended by a period \n        of six months after the date the patent expires (including any \n        patent extensions); or\n            ``(B) if the drug is the subject of a listed patent for \n        which a certification has been submitted under section \n        505(b)(2)(A)(iv) or section 505(j)(2)(A)(vii)(IV), and in the \n        patent infringement litigation resulting from the certification \n        the court determines that the patent is valid and would be \n        infringed, the period during which an application may not be \n        approved under section 505(c)(3) or section 505(j)(4)(B) shall \n        be extended by a period of six months after the date the patent \n        expires (including any patent extensions).\n    ``(d) Conduct of Pediatric Studies.--\n            ``(1) Agreement for studies.--The Secretary may, pursuant \n        to the written request for studies, after consultation with\n                    ``(A) the sponsor of an application for an \n                investigational new drug under section 505(i),\n                    ``(B) the sponsor of an application for a drug \n                under section 505(b)(1), or\n                    ``(C) the holder of an approved application for a \n                drug under section 505(b)(1), agree with the sponsor or \n                holder for the conduct of pediatric studies for such \n                drug.\n            ``(2) Written protocols to meet the studies requirement.--\n        If the sponsor or holder and the Secretary agree upon written \n        protocols for such studies, the studies requirement of \n        subsection (a) or (c) is satisfied upon the completion of the \n        studies and submission of the reports thereof in accordance \n        with the original written request and the written agreement \n        referred to in (1). Not later than 60 days after the submission \n        of the report of the studies, the Secretary shall determine if \n        such studies were or were not conducted in accordance with the \n        original written request and the written agreement and reported \n        in accordance with the requirements of the Secretary for filing \n        and so notify the sponsor or holder.\n            ``(3) Other methods to meet the studies requirement.--If \n        the sponsor or holder and the Secretary have not agreed in \n        writing on the protocols for the studies, the studies \n        requirement of subsection (a) or (c) is satisfied when such \n        studies have been completed and the reports accepted by the \n        Secretary. Not later than 90 days after the submission of the \n        reports of the studies, the Secretary shall accept or reject \n        such reports and so notify the sponsor or holder. The \n        Secretary's only responsibility in accepting or rejecting the \n        reports shall be to determine, within 90 days, whether the \n        studies fairly respond to the written request, whether such \n        studies have been conducted in accordance with commonly \n        accepted scientific principles and protocols, and whether such \n        studies have been reported in accordance with the requirements \n        of the Secretary for filing.\n    ``(e) Delay of Effective Date for Certain Applications; Period of \nMarket Exclusivity.--If the Secretary determines that the acceptance or \napproval of an application under section 505(b)(2) or 505(j) for a drug \nmay occur after submission of reports of pediatric studies under this \nsection, which were submitted prior to the expiration of the patent \n(including any patent extension) or market exclusivity protection, but \nbefore the Secretary has determined whether the requirements of \nsubsection (d) have been satisfied, the Secretary shall delay the \nacceptance or approval under section 505(b)(2) or 505(j), respectively, \nuntil the determination under subsection (d) is made, but such delay \nshall not exceed 90 days. In the event that requirements of this \nsection are satisfied, the applicable period of market exclusivity \nreferred to in subsection (a) or (c) shall be deemed to have been \nrunning during the period of delay.\n    ``(f) Notice of Determinations on Studies Requirement.--The \nSecretary shall publish notice of any determination that the \nrequirements of subsection (d) have been met and that submissions and \napprovals under section 505(b)(2) or (j) for a drug will be subject to \nthe provisions of this section.\n    ``(g) Definitions.--As used in this section, the term `pediatric \nstudies' or `studies' means at least one clinical investigation (that, \nat the Secretary's discretion, may include pharmacokinetic studies) in \npediatric age-groups in which a drug is anticipated to be used.\n    ``(h) Limitation.--The holder of an approved application for a new \ndrug that has already received six months of market exclusivity under \nsubsection (a) or subsection (c) may, if otherwise eligible, obtain six \nmonths of market exclusivity under subsection (c)(1)(B) for a \nsupplemental application; however the holder is not eligible for \nexclusivity under subsection (c)(2).''\n    ``(i) Sunset.--No period of market exclusivity shall be granted \nunder this section based on studies commenced after January 1, 2004. \nThe Secretary shall conduct a study and report to Congress not later \nthan January 1, 2003 based on the experience under the program. The \nstudy and report shall examine all relevant issues, including--\n            ``(1) the effectiveness of the program in improving \n        information about important pediatric uses for approved drugs;\n            ``(2) the adequacy of the incentive provided under this \n        section;\n            ``(3) the economic impact of the program; and\n            ``(4) any suggestions for modification that the Secretary \n        deems appropriate.''."
}